Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, successful product launches, and strategic collaborations, particularly in the Indian market. Despite a decline in PAT, the company maintains a robust cash position and expects sustainable growth. The Q&A reveals optimism about innovative products and market expansion, though there are some uncertainties in biosimilar timelines. Overall, the positive developments, particularly in India, and optimistic guidance outweigh the negatives, suggesting a positive stock price movement.
Key Financial Performance
Revenue Consolidated revenues for the quarter stood at INR 8,727 crores (USD 971 million), a growth of 4.4% year-over-year and a decline of 0.9% sequentially. Growth was driven by strong performance across branded businesses (India, emerging markets, and Nicotine Replacement Therapy) and favorable currency exchange rate movements, partially offset by lower Lenalidomide sales and pricing pressure in U.S. and Europe Generics.
Gross Profit Margin Consolidated gross profit margin for the quarter was 53.6%, a decrease of 505 basis points year-over-year and 104 basis points sequentially. The decline was due to lower Lenalidomide sales, price erosion in unbranded generic businesses, adverse product mix in PSA, and a onetime provision related to new labor law codes. Adjusted gross margin was 54.1%.
SG&A Spend SG&A spend for the quarter was INR 2,692 crores (USD 300 million), an increase of 12% year-over-year and 2% sequentially. The increase was due to targeted investments in branded franchises, adverse Forex impact, and a onetime provision related to new labor law codes. SG&A spend accounted for 31% of revenue, higher by 199 basis points year-over-year and 82 basis points sequentially. Adjusted SG&A spend as a percentage of revenue was 30%.
R&D Spend R&D spend for the quarter was INR 615 crores (USD 68 million), a decline of 8% year-over-year and flat sequentially. The decrease was due to lower development spends in biosimilars as major investments in abatacept were completed. The spend included a onetime provision related to new labor law codes. Adjusted R&D spend was 6.8% of revenues.
EBITDA EBITDA for the quarter, including other income, stood at INR 2,049 crores (USD 228 million), a decline of 11% year-over-year and 13% sequentially. EBITDA margin was 23.5%, lower by 401 basis points year-over-year and 322 basis points sequentially. Adjusted EBITDA margin was 24.8%.
Profit Before Tax (PBT) Profit before tax for the quarter stood at INR 1,543 crores (USD 172 million), with PBT as a percentage of revenue at 17.7%. Excluding the onetime provision related to new labor law codes, the PBT margin was 19%. The increase in net finance income contributed to the PBT.
Profit After Tax (PAT) Profit after tax attributable to equity holders for the quarter was INR 1,210 crores (USD 135 million), a decline of 14% year-over-year and 16% sequentially. PAT as a percentage of revenue was 13.9% before adjusting for the onetime provision related to new labor law codes.
Free Cash Flow Free cash flow generated during the quarter was INR 374 crores (USD 42 million).
Net Cash Surplus Net cash surplus as of December 31, 2025, was INR 3,069 crores (USD 342 million).
CapEx CapEx cash outflow for the quarter stood at INR 669 crores (USD 75 million).
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Semaglutide Injection: Received marketing authorization in India and started filing in various emerging markets. Awaiting response from Canadian regulatory agency after addressing their request for additional information.
Abatacept Biosimilar: Completed filing of the Biologics License Application (BLA) for IV presentation in December 2025.
Denosumab Biosimilar: Received European Commission approval and launched in Germany. Preparations underway for launches in the UK and other European countries.
Hevaxin Vaccine: Launched a novel recombinant vaccine for Hepatitis-E virus infection in India.
Emerging Markets: Delivered robust growth of 32% year-on-year and 15% sequentially, driven by new product launches and favorable Forex. Introduced 30 new products across countries.
India Business: Reported 19% year-on-year growth, driven by innovation franchise, new brand launches, price increases, and higher volumes. Launched 2 new brands.
Russia Business: Achieved 21% year-on-year growth despite adverse macroeconomic conditions.
North America Generics: Revenue declined by 16% year-on-year due to lower Lenalidomide sales and price erosion. Launched 6 new products.
European Generics: Reported 4% year-on-year growth, supported by the Nicotine Replacement Therapy portfolio and new product launches.
Operational Efficiencies: Achieved EBITDA margin of 24.8% (adjusted for one-time provision). Continued focus on driving gross efficiencies and advancing key pipeline programs.
Integration of Nicotine Replacement Therapy Business: 85% of the business by value is under operational control. Integration expected to be completed by the end of the fiscal year.
Sustainability Practices: Announced a science-based net zero climate target by FY2045. Leadership position in CDP Water Security & Climate Change categories for 2025.
Strategic Collaboration with Immutep: Entered into a collaboration for commercialization of Eftilagimod Alfa, a novel immunotherapy oncology drug, with potential regulatory and commercial milestones up to $350 million.
Focus on Differentiated R&D: Investing in peptides and biosimilars, with 28 global generic filings completed during the quarter.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth: Revenue growth of 4.4% year-over-year was impacted by lower Lenalidomide sales and continued pricing pressure in the U.S. and Europe Generics.
Gross Profit Margin: Gross profit margin declined by 505 basis points year-over-year due to lower Lenalidomide sales, price erosion in unbranded generic businesses, and adverse product mix.
EBITDA Margin: EBITDA margin declined by 401 basis points year-over-year, impacted by a one-time provision related to new labor law codes in India.
R&D Spend: R&D spend declined by 8% year-over-year, reflecting lower development spends in biosimilars and a one-time provision related to new labor law codes.
Regulatory Challenges: Received a notice of noncompliance from Canadian authorities for semaglutide injection and a complete response letter from USFDA for denosumab biosimilar BLA, indicating regulatory hurdles.
Facility Inspections: USFDA inspections of facilities resulted in observations, including five observations at the Srikakulam facility and outstanding issues at the Bachupally biologics facility.
Price Erosion: Price erosion in key products in the U.S. and Europe Generics markets continues to impact revenue.
Integration of Acquired Business: Integration of the Nicotine Replacement Therapy business is ongoing, with 85% under operational control, but full integration is still pending.
Emerging Market Conditions: Adverse macroeconomic conditions in Russia, though mitigated by growth, present ongoing challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued growth in its base business, excluding Lenalidomide, which has already shown double-digit growth. Revenue growth is also anticipated to be supported by favorable Forex movements.
EBITDA Margin: The company projects an adjusted EBITDA margin of approximately 25%, excluding one-time provisions related to new labor law codes in India.
Pipeline Products: The company is advancing key pipeline products, including semaglutide and abatacept. Semaglutide injection has received marketing authorization in India, and filings in emerging markets are underway. The biologics license application for abatacept biosimilar has been completed.
Product Launches: The company plans to continue launching new products across various markets, with 30 new products introduced in emerging markets during the quarter. Further launches are expected to strengthen the portfolio.
Nicotine Replacement Therapy Business: The integration of the acquired Nicotine Replacement Therapy business is expected to be largely completed by the end of the fiscal year.
Market Expansion: The company is focusing on expanding its presence in emerging markets, with robust growth already observed in regions like Russia and India. New product launches and favorable Forex are expected to drive further growth.
Sustainability Goals: The company has committed to a science-based net zero climate target by FY2045, positioning itself as a leader in sustainability within the Indian pharmaceutical sector.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the organic growth rate for the India business excluding acquisitions?
A:The organic growth rate for the India business is between 17% and 18%, excluding acquisitions.
Q:What is driving the strong growth in the India business, and is it sustainable?
A:The growth is driven by the performance of innovative products, with some brands in their second or third year since launch. The strategy of introducing innovation to India is working. The growth in the mid-teens range is considered sustainable.
Q:What portion of sales does the innovative portfolio contribute to the India business?
A:The innovative portfolio contributes approximately 10% to 15% of sales.
Q:What is the timeline for semaglutide approval and launch in Canada?
A:The goal date for semaglutide approval in Canada is May, but approval could happen anytime between now and May. The company is preparing for a launch between the end of February and May.
Q:Is the growth in the India business influenced by spillover benefits from the prior quarter due to GST disruption?
A:No, the growth in the India business is not influenced by spillover benefits from the prior quarter due to GST disruption.
Q:What are the expectations for semaglutide pricing and competition in Canada and other markets?
A:The pricing expectations remain in the range of $20 to $70 per unit, with most markets on the lower end. The company expects initial healthier prices but anticipates competitive markets over time.
Q:How much has generic Lenalidomide contributed to EBITDA margins, and what are the expectations for Q4 and FY '27?
A:The contribution of generic Lenalidomide to EBITDA margins is confidential due to a confidentiality agreement. The decline in the U.S. market is primarily due to Lenalidomide, and without it, the company has grown. EBITDA margins are expected to be in the range of 50% to 55%.
Q:What are the timelines for denosumab and rituximab in the U.S.?
A:Denosumab is likely to launch in the second quarter of FY '27 or later, depending on the USFDA's response to the deficiency letter. Rituximab approval is expected after reinspection, likely not within the next six months.
Q:What is the status of semaglutide launch in India and other countries?
A:Semaglutide will be launched in India on March 21. In Canada, the launch is expected between February and May. The company is also registering the product in over 80 markets, with significant launches in Brazil and Turkey around July.
Q:What is the impact of biosimilar delays on the company's estimates and timelines?
A:Rituximab launch in the U.S. is delayed by over a year, while denosumab is delayed by at least six months. Abatacept is on track for approval in late 2026 for IV and early 2028 for subcutaneous.
Q:What is the company's R&D spend guidance?
A:The R&D spend guidance remains at 7% to 8% of sales, with continued investment in new molecules and collaborations.
Q:What is the outlook for SG&A expenses?
A:SG&A expenses are expected to grow at a slower pace than sales, with discretionary costs being tightly controlled.
Q:What is the growth outlook for the European market excluding NRT?
A:The European market excluding NRT is expected to grow in double digits, with biosimilar launches contributing to growth.
Q:What is the status of semaglutide tablets filing in India?
A:The company does not anticipate significant delays in approval due to on-site verification of Phase III trial data. There is no litigation overhang for the launch of tablets in India.
Q:What is the growth outlook for the India business with the semaglutide launch and new acquisitions?
A:The India business is expected to sustain growth of 15% to 16%, with potential for higher growth depending on scenarios and business development.
Q:What is the expected gross margin for Global Generics and PSA post-Lenalidomide?
A:The gross margin for Global Generics and PSA is expected to be in the range of 50% to 55%.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the contribution of generic Lenalidomide to EBITDA margins, citing confidentiality agreements. Additionally, timelines for denosumab and rituximab approvals remain uncertain, with management providing broad estimates rather than specific dates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adjusting labor
Council welcome
Europe Generics
FY Dr
FY pleasure
Forex margin
Forex provision
Generics margin
Healthcare generic
INR USD
India provision
Instructions session
Israeli Chief
Laboratories Limited
Limited interest
Limited medium
MVN
Officer
PBT
PSA
RD spend
RUB
USD decline
USD increase
code provision
comparison
contract
crore USD
crore finance
decline basis
exchange rate
hedge
income INR
labor law
law code
mix
provision labor
provision margin
rate INR
spend revenue
RDY Transcript
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Positive1-21
The earnings call highlights strong revenue growth, successful product launches, and strategic collaborations, particularly in the Indian market. Despite a decline in PAT, the company maintains a robust cash position and expects sustainable growth. The Q&A reveals optimism about innovative products and market expansion, though there are some uncertainties in biosimilar timelines. Overall, the positive developments, particularly in India, and optimistic guidance outweigh the negatives, suggesting a positive stock price movement.
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Unknown10-24
The earnings call reveals mixed aspects: stable financial health with strategic R&D investments and promising biosimilar launches, but concerns over competitive pressures and legal challenges. Strong growth in India and emerging markets is positive, but price erosion in the U.S. and unclear guidance on semaglutide pricing impact sentiments. Given these balanced positives and negatives, a neutral stock reaction is expected.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Unknown5-9
Financial performance is mixed with strong EBITDA growth but declining annual EBITDA margin. Concerns include rising expenses, unclear tariff impacts, and competitive pressures on semaglutide. Positive aspects are stable US price erosion and strong US business growth. Management's lack of clarity on tariffs and severance costs adds uncertainty. Overall, the mixed signals suggest a neutral stock price movement.
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Positive11-5
The earnings call presents a generally positive outlook with strong profit margins and increased R&D investment. The Q&A section highlights stable pricing in North America, potential growth acceleration, and high-value launches expected soon. Despite some unclear responses, the overall sentiment is optimistic with a focus on future growth, particularly in biosimilars and the US market. This aligns with a positive short-term stock price prediction.
RDY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
